Press release – 29 Nov 2017

The Laboratory of Adaptive Immunity and Homeostasis enters a strategic research collaboration with a leading pharmaceutical company

Jan T. Andersen (photo: UiO/Ø.H. Horgmo)
Jan T. Andersen (photo: UiO/Ø.H. Horgmo)

The Laboratory of Adaptive Immunity and Homeostasis, headed by Jan Terje Andersen, at Oslo University Hospital and University of Oslo, is combining structural and biophysical approaches with cellular and animal studies to unravel how the neonatal Fc receptor (FcRn) acts as a key player in regulation of the long serum half-life of albumin and IgG antibodies. The research group has signed a strategic research agreement with Roche Diagnostics GmbH where the aim will be to gain an in-depth understanding on how FcRn is regulating transport of engineered IgG antibodies in different types of cells. The agreement is part of the Roche Postdoctoral Fellowship program.

Jan Terje Andersen commented; “We are very pleased to announce our collaboration with a leading pharmaceutical company within the antibody field. Antibodies are blockbusters and the fastest growing class of therapeutic biologics, and our laboratory is actively studying how antibodies are transported within and across different types of cells - knowledge that may pave the way for design of IgG therapeutics with improved binding and transport properties”.  

For further information, please visit

https://www.ous-research.no/andersen/

https://www.facebook.com/AndersenLaboratory/